- Home
- VYNE vs CING Comparison
VYNE vs CING Comparison
Compare VYNE & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- CING
- Stock Information
- Founded
- VYNE 2003
- CING 2012
- Country
- VYNE United States
- CING United States
- Employees
- VYNE N/A
- CING N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- CING Health Care
- Exchange
- VYNE Nasdaq
- CING Nasdaq
- Market Cap
- VYNE 16.0M
- CING 17.3M
- IPO Year
- VYNE 2018
- CING 2021
- Fundamental
- Price
- VYNE $1.46
- CING $5.50
- Analyst Decision
- VYNE Strong Buy
- CING Strong Buy
- Analyst Count
- VYNE 2
- CING 4
- Target Price
- VYNE $6.25
- CING $30.67
- AVG Volume (30 Days)
- VYNE 895.6K
- CING 104.9K
- Earning Date
- VYNE 08-13-2025
- CING 08-12-2025
- Dividend Yield
- VYNE N/A
- CING N/A
- EPS Growth
- VYNE N/A
- CING N/A
- EPS
- VYNE N/A
- CING N/A
- Revenue
- VYNE $605,000.00
- CING N/A
- Revenue This Year
- VYNE $42.51
- CING N/A
- Revenue Next Year
- VYNE N/A
- CING N/A
- P/E Ratio
- VYNE N/A
- CING N/A
- Revenue Growth
- VYNE 43.03
- CING N/A
- 52 Week Low
- VYNE $0.85
- CING $1.80
- 52 Week High
- VYNE $4.30
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- VYNE 56.57
- CING 66.64
- Support Level
- VYNE $1.10
- CING $4.25
- Resistance Level
- VYNE $1.49
- CING $6.01
- Average True Range (ATR)
- VYNE 0.15
- CING 0.34
- MACD
- VYNE -0.00
- CING 0.09
- Stochastic Oscillator
- VYNE 90.45
- CING 71.02
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.